Natunola Releases Year Ended December 2008 Results



    WINCHESTER, ON, April 21 /CNW Telbec/ - Natunola Health Biosciences Inc.
(TSX-V:NHI) ("Natunola") reports that the sales for the year ending December
31, 2008 were $1,961,401, a decline of 16.1% or $376,266 for the twelve months
ended December 31, 2008 versus the comparative period for 2007. This is due to
a decline of $425,138 in sales of the Company's animal nutritional product
lines related to ceasing production and sale of certain low or no margin
products during the year. The decline is also due to a decrease of 39.7% or
$204,771 in sales for the Company's personal care product lines for the twelve
months ended December 31, 2008 versus the comparative period for 2007. The
lower sales are due to the economic slow down and fewer shipments of the
Company's personal care ingredients to its customers. As a result, the Company
recorded a net loss of -$266,010 or -$0.02 per share the period ended December
31, 2008 versus a profit of $114,126 or $0.01 per share for the comparative
period for 2007.
    The sales for the Company's flax product lines increased by 17.3% or
$239,450 for the twelve months ended December 31, 2008 versus the comparative
period for 2007 (December 31, 2008 - $1,625,075; December 31, 2007 -
$1,385,626). This increase is due to the increased awareness and acceptance of
the Company's flax products for the human retail market.
    Cost of sales as a percentage of sales increased by 8.9% for the year
ended December 31, 2008 versus the comparative period for 2007. The increase
is due to the write down of unusable raw materials and finished goods
inventory from discontinued product lines of $67,535 (December 31, 2007 -
$NIL). The increase in cost of sales is also due to the higher fuel and
commodity cost for the year ended December 31, 2008 versus the comparative
period for 2007. As a result, gross margins decreased significantly.
    General expenses were 65.4% of the sales for the twelve months ended
December 31, 2008 versus 55.3% for the same period for 2007. This percentage
increase is due to the lower sales, a recorded bad debt of $34,261 and a
higher stock option expense which was expensed as director fee of $61,200 for
the twelve months ended December 31, 2008 versus $34,000 for the same period
for 2007.
    The Company's own brand of retail omega-3 flax products, Natunola(R)
health's delight, has been launched into many stores across Canada. Management
is committed to expanding the retail brand products which will include the
introduction of the line into US market and thus should create increase
revenue for the Company.

    Some of the statements contained in the release are forward-looking
statements, such as estimates and statements that describe the Company's
future plans, objectives or goals, including words to the effect that the
Company or management expects a stated condition or result to occur. Since
forward-looking statements address future events and conditions, by their very
nature, they involve inherent risks and uncertainties. Actual results in each
case could differ materially from those currently anticipated in such
statements.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this press release.
    %SEDAR: 00009761E




For further information:

For further information: Dr. Murray McLaughlin, Chairman, Natunola
Health Biosciences Inc., (613) 774-0008

Organization Profile

Natunola Health Biosciences Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890